He was the co-founder and chief scientific officer of Stemcentrx, which was acquired by AbbVie in 2016. Scott trained as a postdoctoral scholar at Stanford University in the laboratory of Dr. Irving L. Weissman, where he was awarded American Cancer Society and Stanford Immunology fellowships, and was subsequently a Sr. Scientist at OncoMed Pharmaceuticals. In 2005, Scott was recognized by the British Council as one of eight outstanding young US-based researchers in the field of stem cell biology.